BackOpus Genetics Overview

Opus Genetics Current Cash

Track Opus Genetics's current cash ($89M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$88.81M
↑ 173.87% YoYΔ $56.38M vs prior year quarter

Peer trimmed avg / median

Loading

Opus Genetics Current Cash History

Loading

Opus Genetics vs. peers: Current Cash Comparison

Loading

Opus Genetics Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Opus Genetics (IRD) FAQ

Opus Genetics (IRD) currently reports a current cash of $89M as of June 2026. That compares with $32M in the prior-year period — up 173.9% year over year. Use the charts on this page to explore Opus Genetics's current cash history and peer comparisons.

Opus Genetics's current cash increased from $32M to $89M — a 173.9% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Opus Genetics reported $89M in current cash as of June 2026. That compares with $32M in the prior-year period — up 173.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current current cash of $89M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Opus Genetics, and consider following IRD for alerts when major investors trade the stock.

Opus Genetics is classified in the Healthcare sector. On current cash, it currently shows $89M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing IRD with unrelated industries.